Sort
48,018 grants matching “immunotherapy”
Cancer immunotherapy
$594,136Eytan Ruppin · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Molecular Control of Plasmacytoid Dendritic Cell Development and Function
$594,130Boris Reizis · New York University School Of Medicine · R37 · FY2019 · AI
Molecular Control of Plasmacytoid Dendritic Cell Development and Function
$594,130Boris Reizis · New York University School Of Medicine · R37 · FY2018 · AI
RIG-I Activating Nanoparticles for Immunopotentiation
$594,047John Tanner Wilson · Vanderbilt University · R01 · FY2023 · EB
(PQ3) Immune epigenetic biomarkers of bladder cancer outcomes
$593,972Brock Clarke Christensen · Dartmouth College · R01 · FY2019 · CA
Identifying therapeutic pathways targeting medulloblastoma-immune cell interactions
$593,964Ernest Fraenkel · Massachusetts Institute Of Technology · U01 · FY2021 · CA
Illumina NovaSeq 6000 DNA Sequencing System
$593,853Yehia Mechref · Texas Tech University · S10 · FY2018 · OD
Decoupling acute toxicities and antitumor efficacy in adoptive cell therapy
$593,810Yong Lu · Methodist Hospital Research Institute · R01 · FY2025 · CA
Autoimmune Mechanisms in Human Myocarditis
$593,699Madeleine W. Cunningham · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2017 · HL
AIDS CLINICAL TRIALS
$593,618Seattle Children'S Hospital · U01 · FY2001 · AI
Molecular and Cellular Immunology
$593,525Jason G. Cyster · University Of California, San Francisco · T32 · FY2023 · AI
Multiscale analysis of metabolic inflammation as a driver of breast cancer
$593,459Gerald V Denis · Boston University Medical Campus · U01 · FY2020 · CA
PET Studies of Serotonin and Amyloid in MCI
$593,446Gwenn S Smith · Johns Hopkins University · R01 · FY2012 · AG
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response
$593,411Lauren Averett Byers · University Of Tx Md Anderson Can Ctr · U01 · FY2022 · CA
Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition
$593,391Jeffrey S Weber · New York University School Of Medicine · R01 · FY2021 · CA
Developing a Human in Mouse Cancer Model with a Completely Humanized Stroma
$593,295Ronald J Buckanovich · Magee-Women'S Res Inst And Foundation · R01 · FY2018 · CA
Targeting Fibroblast Discoidin Domain Receptor 2 for Immunotherapy to Pulmonary Fibrosis
$593,218Kevin Keewoun Kim · University Of Michigan At Ann Arbor · R01 · FY2024 · HL
Influences of the Microenvironment on Cancer Stem Cells
$593,215Owen N Witte · University Of California Los Angeles · U01 · FY2015 · CA
Novel molecular imaging approaches to monitor gene and cell-based therapies
$593,141Caius Gabriel Radu · University Of California Los Angeles · R01 · FY2012 · CA
Mast cell regulation of Th2 induction and tolerance breakdown in food allergy
$593,108Hans C. Oettgen · Boston Children'S Hospital · R01 · FY2021 · AI
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response
$593,078Brendan D Curti · Providence Portland Medical Center · R01 · FY2021 · CA
Dysregulated Complement Pathway in Macrophage Reprogramming and Progression of HCC in MASH
$593,042Renumathy Dhanasekaran · Stanford University · R37 · FY2025 · CA
The role of IL-6/STAT3 signaling in CIC-DUX4 fusion sarcoma metastasis and immunosuppression
$593,028Hua E Yu · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
$593,023Isabelle Caroline Le Poole · Northwestern University At Chicago · R01 · FY2025 · HL
GENE EXPRESSION ANALYSIS OF CIRCULATING TUMOR CELLS: A NEXT-GENERATION BIOMARKER TO PREDICT IMMUNOTHERAPY RESPONSE IN METASTATIC CLEAR CELL RENAL CELL CARCINOMA
$592,859University Of Wisconsin System · · FY2024 · Defense Health Agency